Claritin-D Indications and Dosage
- allergic rhinitis
- common cold
Claritin-D Indications and Dosage
For the temporary relief of symptoms due to seasonal allergic rhinitis or the common cold, including sneezing, runny nose, itching of the nose or throat, nasal congestion, and itchy, watery eyes:
Oral dosage (Claritin-D® 12-HOUR extended-release tablets):
Adults and adolescents >= 12 years: 1 tablet PO every 12 hours (each Claritin-D® 12-HOUR extended-release tablet contains 5 mg of loratadine and 120 mg pseudoephedrine).
Elderly: See adult dosage. It is prudent to initiate dosage with the individual components (loratadine and immediate-release pseudoephedrine) or the shorter-acting combination formulation (Claritin-D® 12-HOUR) in elderly patients until drug tolerance (especially to the pseudoephedrine component) is established. Elderly patients are more likely to have adverse reactions to sympathetic amines and reduced renal function (see dosage for patients with renal impairment).
Children < 12 years: Safe and effective use has not been established.
Oral dosage (Claritin-D® 24-HOUR extended-release tablets):
Adults and adolescents >= 12 years: 1 tablet PO once daily (each Claritin-D® 24-HOUR extended-release tablet contains 10 mg of loratadine and 240 mg pseudoephedrine).
Elderly: See adult dosage. It is prudent to initiate dosage with the individual components (loratadine and immediate-release pseudoephedrine) or the shorter-acting combination formulation (Claritin-D® 12-HOUR) in elderly patients until drug tolerance (especially to the pseudoephedrine component) is established. Elderly patients are more likely to have adverse reactions to sympathetic amines and reduced renal function (see dosage for patients with renal impairment).
Children < 12 years: Safe and effective use has not been established.
Maximum Dosage Limits:
- Adults: 10 mg/day PO loratadine; 240 mg/day PO pseudoephedrine.
- Elderly: 10 mg/day PO loratadine; 240 mg/day PO pseudoephedrine.
- Adolescents: 10 mg/day PO loratadine; 240 mg/day PO pseudoephedrine.
- Children: Safe and effective use has not been established.
Patients with hepatic impairment:
The fixed combination of loratadine and pseudoephedrine should be avoided in hepatic disease. In hepatic disease, the clearance of loratadine is reduced.
Patients with renal impairment:
CrCl < 30 ml/min: reduce Claritin-D® 24-HOUR starting dosage to 1 tablet PO every other day or reduce Claritin-D® 12-HOUR starting dosage to 1 tablet PO once daily.
Intermittent hemodialysis:
See dosage for patients with renal impairment. Loratadine is not removed by hemodialysis. Hemodialysis minimally removes pseudoephedrine from the blood.
[ Last revised: 8/23/2004 2:12:00 PM ]
Related entries
Syndicate
|
